Home › Forums › Clinical Practice › prescribing GLP-1s in psychiatry
- This topic has 7 replies, 7 voices, and was last updated 1 year, 8 months ago by
Shannon Minnehan.
-
AuthorPosts
-
March 18, 2025 at 5:20 pm #1322
Emily Standish
Hello everyone,
First, I want to express my gratitude for this organization and these forums. This is an invaluable resource, and I’m so thankful to be able to connect with other like-minded professionals. It’s encouraging to see how much knowledge and support this community offers.
I’m reaching out today with a question regarding the prescribing of GLP-1 agonists within a psychiatry residency program. I am a clinical psychologist/faculty in the residency program, and I’ve been following some recent discussions at my institution, encouraging residents to prescribe GLP-1s within the outpatient psychiatry clinic. Leadership at our clinic has expressed a desire to prescribe these medications to patients in order to “bend the mortality curve.”
I have concerns about the broader implications of such an approach in psychiatry, especially in terms of reinforcing anti-fat bias. I’m also unsure if our providers are sufficiently trained to handle the emotional and physical complexities of these medications. However, I worry that my concerns may be perceived as overly cautious or unwarranted by others, especially given the current focus on weight loss in the department. I will note that my department, by and large, operates within a weight-centric model, and I am the only faculty member (that I am aware of) raising concerns about the harms of weight stigma/anti-fat bias in medicine.
I want to make sure I’m not missing anything here. Is anyone here familiar with whether this is common practice in other residency programs? Are there any resources or research that could help me form a well-informed opinion on the matter? I found the GLP-1 consent document on the MSSI website, which was very helpful. I’m hoping to compile some additional references to present to the leadership in our department to encourage a more in-depth conversation about whether this is a direction we should be pursuing within our clinic.
Thank you so much in advance for your thoughts and any resources you can point me to!
Best regards,
Emily Standish
March 19, 2025 at 9:48 am #1324Andrea Westby
Emily – wow. I think your concerns are very valid.
I did not attend psychiatry residency, so I have a lot of questions. Are psychiatrists prescribing statin therapy for people with mortality risk of cardiovascular events, or blood pressure, or diabetes? It seems out of scope to me to be prescribing GLP-1 medications for weight loss in a psychiatry practice, given that the medications aren’t currently FDA-approved for psychiatric conditions (I know there has been interest for research on their use for alcohol use disorder and binge eating disorder, but I don’t think that data currently exists), and their impact is far beyond psychiatric outcomes.
Also, is there data that GLP-1s “bend the mortality curve”? If there is, I might be missing it.
But I’d be open to hearing what others think.
March 19, 2025 at 2:13 pm #1329Sarah Halter
I’m in family medicine. I’ve seen an uptick in patients coming to me from their psych providers having been told to “talk to their PCP” about weight loss medication (almost always a GLP1ra). This is usually in patients who are on psychotropic medications used to manage psychosis but I’ve also seen in patients not on one of those drugs.
I don’t have a resource for this, but plenty of my patients have expressed surprise, feeling like this recommendation came out of left field. It’s damaged their relationship with their psych provider. I’ve had a few people tell me they’re not going to go back to their psychiatrist because of the broken trust – “Why are they telling me I need to lose weight? Where did this come from? I thought we were managing my depression?”
It’s frustrating – of obvious reasons – to see this. These patients are struggling with mental health difficulties and now they’re unexpectedly facing the harms of weight-stigma by someone who should be on their side?
I usually end up going into my spiel about how weight =/= health, the harms of trying to shrink one’s body just to shrink one’s body, etc. Granted, I present myself as a weight-inclusive doctor, so my patients are usually coming to me expecting a weight-inclusivity approach. They already know how I’m going to respond to this.
That’s so tough, Emily. And I think we’re going to be dealing with this more and more as GLP1ras are being presented as “miracle drugs” because of their role in reducing cardiovascular risk in diabetics. They fix everything, right?
I too would be very concerned about the scope of practice concern her. I do prescribe GLP1ras because I have a lot of diabetics. And you better believe I talk about the potential risks, what we know and what we don’t know about them, etc.
March 20, 2025 at 2:19 pm #1334Jessica Friedman
I echo some of the same concerns that have already been posted. Some additional thoughts:1) I assume that some of the rationale for prescribing GLP1-RAs to patients in a psychiatry residency is around the metabolic adverse effects of atypical antipsychotics. I imagine that it’s quite challenging to have these medications that can be so effective from a psychiatric perspective and yet carry significant metabolic and weight-related side effects. I can understand wanting to have a tool to be able to offer patients to mitigate those side effects. That being said:
– I am not aware of any studies that have looked at patient-centered outcomes of GLP1-RAs and antipsychotics. I think it’s reasonable to expect the same short-term benefits regarding weight, diabetes incidence, etc. but also to note that the evidence base isn’t there and that this is an off-label indication. I recognize that so much in psychiatry is off-label, and this is also a teachable opportunity.– Are these providers being taught to engage in informed-consent conversations around prescribing atypical antipsychotics? A lot of my patients are unaware of the metabolic side effects of antipsychotics until they happen. If the residents are going to be advising weight loss after the fact, they should also be discussing it before the fact.- Are providers being taught to screen for current or prior disordered eating before prescribing these medications? Given the likely higher-than-average incidence of eating disorders in psychiatric practice, this seems to be a necessary (though often forgotten) part of counseling patients about weight.2) I wonder what it could look like to have a local family physician or internist (ideally one with a weigh-neutral or weight-inclusive approach) talk to them about what it looks like in practice to prescribe those medications, including duration of treatment, side effect management, discontinuation rates, cost/insurance coverage, prior authorization, etc. I see this as an opportunity for harm reduction.Jess Friedman, MD, MPHBaltimore, Maryland
March 21, 2025 at 10:00 am #1342Mara Gordon
Thanks so much for starting this thoughtful conversation. I realize you were writing about psychiatrists themselves prescribing GLP1s, but it made me think of a related issue that I’m experiencing a lot of, which is specialists telling my patients to come talk to ME about GLP1s after the specialist initiates the discussion. As a primary care doc, I unfortunately feel like this phenomenon is one of the challenges of being a generalist. “Tell your PCP to [check your vitamin D] [check your hormones] [prescribe your oxycodone]” etc etc etc. It never stops, and probably won’t stop anytime soon. I try to approach specialty-initiated discussions about GLP1s the same way I’d approach the conversation if my patient brings it up: Assess the patient’s understanding of the situation, try to elicit their concerns and hopes, take into account the objective and subjective medical information, and perform shared decision-making about the plan going forward. And of course, re-emphasize my commitment to size-inclusive medicine and using treatment goals other than reduction of BMI. (Easy, right?) I do try not to throw other docs under the bus, even if I disagree with their assessment, but it can be very challenging sometimes. (The cardiologist who wrote in a note that my frail 95 year old patient should get down to a BMI of 25! Grrrrr!!! I have to only hope that was auto-populated info..) Would love to hear how others are dealing with this, too. All best, MaraMarch 21, 2025 at 12:34 pm #1344Whitney Thomas
Hi all–
I’m a psychiatrist and continue to be involved in a limited way with resident teaching. A few things that I can add:
- Psychiatrists are just as susceptible to weight bias as any other specialty. One piece that is worth considering that hasn’t been mentioned yet is that we are also frequently trained in motivational interviewing (namely for substance use disorders), although this can also get conflated with “lifestyle medicine” and thus be used to push interventions around weight loss/dieting. I’ve also seen a surge of psychiatrists getting boarded in “o****** medicine.”
- Every psychiatrist should be screening for eating disorders at first appointment, though again I don’t think that there is enough recognition around the prevalence of eating disorders across all body sizes. One would posit that though EDs are being screened for, some may be screened out due to provider bias. Finally, some institutions are very “siloed” — a psychiatrist who mainly treats psychosis and thus is more likely to prescribe an SGA may only very rarely treat EDs.
- Re: SGAs — this is a trickier discussion. Of course these medications are associated with weight gain. Psychiatrists (outside of en emergent setting) are generally good about counseling about the risk of weight gain, DM2, HLD. Patients should also been screened for DM2 via HbA1c and HLD via lipid panel yearly while on an SGA. I order this on my own if pt does not have a PCP. I know many psychiatrists will start metformin for patients, but do not hear psychiatrists routinely starting insulin, statins, etc.
- An interesting piece to consider here is that SGAs were pivoted to because first generation antipsychotics are more often a/w TD and SGAs are also thought to better treat negative symptoms due to their different mechanism of action. There is something really icky (scientific term) about this to me because there are rumblings of discussion that perhaps we should turn more back towards meds with a higher risk of TD so “at least they won’t be gaining weight.” As if the stigma of having TD and being in a larger body are somehow on the same level.
- I have increasingly seen posts on psychiatrist FB groups that I am a member of about starting GLP1s for weight gain 2/2 medications. They’re typically loaded with weight stigma and plenty of posts around how they have helped the psychiatrist themselves feel more confident, etc. There is a mix of what seems to be ill informed, but good intentions which point out that our patients are exposed to more stigma than the average joe at baseline and this is one way to “help” with that.
- I personally have come up against a brick wall when pointing to an increased risk of SI as outlined in Wegovy’s package insert as well as the fact that patients with SPMI are excluded from these studies. The response I typically get when pointing out the latter is “of course they didn’t include SPMI and they never will.”
- On a practical level, I find it to be a pretty tough sell for many of my patients to consider LAIAs. I wonder how they plan to get a population on board with taking weekly injections when it’s so hard to get them into clinic q3-4wks for LAIAs.
- Regarding the initial post’s question about how to broach this with a training program: I think there could be a really valuable opening here for a discussion around countertransference in the dr/pt relationship. What is driving a specific psychiatrist to consider this as an intervention that is appropriate for us to provide? How might the psychiatrist imagine feeling if this was brought up to them in this setting if they were the patient?
I appreciate you bringing up this important topic of discussion, I’ve been wondering about it too.
March 22, 2025 at 9:54 am #1345Emily Standish
Hello again,
I can’t thank you all enough for these incredibly validating, thoughtful and informative responses! The weight stigma is so entrenched in my clinic that I honestly start to question myself sometimes—it’s helpful to know that I have valid concerns and that I am indeed not losing my mind! It seems there could be some issues related to scope, informed consent, insufficient screening for ED/disordered eating, insufficient data etc. Also seems like there could be some very helpful educational opportunities for residents. I have much to unpack and consider in these above responses—thanks again.
I have started to bring up my concerns related to GLP-1s in our psychiatry clinic and have received a couple of counter arguments from providers. From what I can gather, the push to prescribe these medications is mostly related to a perceived “public health imperative” to address the “Ob*sity epidemic.” Surprisingly, no one is even mentioning metabolic and weight side effects associated with atypical antipsychotics. A psychiatrist in my clinic presented the argument that psychiatrists should prescribe weight loss medications to help people lose weight in the same way psychiatrists prescribe medications for smoking cessation?! I was also sent a JAMA opinion article taking a public health stance that acknowledged that weight stigma is a thing, but that efforts to address weight stigma are evolving into a “narrative that obscures the importance of ob*sity-related morbidity and mortality (Celletti, Branca & Farrar, 2024).” Ughhh. At the moment, I am struggling to figure out the best and most productive way to respond to this (somewhat unexpected) public health retort.
I appreciate any additional thoughts anyone may have. I’ll continue to use these insights to help inform what I hope will be positive, productive and educational discussions within our clinic (and hold on to hope that I am not just screaming into the void…). Looking forward to continuing these conversations and learning from you all.
March 23, 2025 at 2:55 pm #1346Shannon Minnehan
I am a psychiatric nurse practitioner treating patients with a broad range of eating disorders. Unfortunately my experience with GLP-1s is taking patients with anorexia nervosa (or ARFID) off of them (after they have been procured by the patient or prescribed without any history taken).
I echo what has been said above by others, and also agree with the difficulties of the siloed nature of the medical system. It is what makes us so adept at caring for certain populations, but also (without research across specialties) blind to the complexities of other aspects of health. I think my experiences in treating patients with ED likely obscures my judgment at times as well, it is the population I advocate and care for. I also am willing to look at other perspectives, which is not usually the case when I try to explain to others how to see things from an ED perspective. The brick wall is real. Why is “ob*sity” the public health concern? Are not eating disorders a public health concern? The Harvard School of Public Health thinks so. (https://hsph.harvard.edu/research/eating-disorders-striped/) Isn’t the weight centered narrative the one obscuring the real issue?
I have trouble understanding why those with such strong feelings about promoting these meds are unable to look through a wider lens. As Dr Thomas wrote above, it is a real opportunity to look at the countertransference, the lack of individualized care and the disregard for adequate screening.
I am so grateful for this group, and I wish you, Emily, luck and courage in having these discussions with your colleagues.
-
AuthorPosts
- You must be logged in to reply to this topic.